VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma
Phase 1
Active, not recruiting
- Conditions
- Recurrent Glioblastoma
- Interventions
- Biological: VXM01Biological: Avelumab
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT03750071
- Locations
- 🇩🇪
Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany
🇩🇪Neurology Clinic, Mannheim, Germany
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT02718443
- Locations
- 🇩🇪
Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT02718430
- Locations
- 🇩🇪
National Center of Tumor Diseases, Heidelberg, Germany
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
Phase 1
Completed
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Biological: PlaceboBiological: VXM01
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT01486329
- Locations
- 🇩🇪
Clinic of General Surgery, Heidelberg, Germany
© Copyright 2025. All Rights Reserved by MedPath